- Home
- ULBI vs AVTX Comparison
ULBI vs AVTX Comparison
Compare ULBI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULBI
- AVTX
- Stock Information
- Founded
- ULBI 1990
- AVTX 2011
- Country
- ULBI United States
- AVTX United States
- Employees
- ULBI N/A
- AVTX N/A
- Industry
- ULBI Industrial Machinery/Components
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- ULBI Miscellaneous
- AVTX Health Care
- Exchange
- ULBI Nasdaq
- AVTX Nasdaq
- Market Cap
- ULBI 98.1M
- AVTX 88.4M
- IPO Year
- ULBI 1992
- AVTX 2015
- Fundamental
- Price
- ULBI $4.28
- AVTX $4.41
- Analyst Decision
- ULBI Strong Buy
- AVTX Strong Buy
- Analyst Count
- ULBI 1
- AVTX 7
- Target Price
- ULBI $14.00
- AVTX $34.33
- AVG Volume (30 Days)
- ULBI 77.2K
- AVTX 69.6K
- Earning Date
- ULBI 04-28-2025
- AVTX 05-12-2025
- Dividend Yield
- ULBI N/A
- AVTX N/A
- EPS Growth
- ULBI N/A
- AVTX N/A
- EPS
- ULBI 0.38
- AVTX N/A
- Revenue
- ULBI $164,456,000.00
- AVTX $441,000.00
- Revenue This Year
- ULBI $35.52
- AVTX N/A
- Revenue Next Year
- ULBI N/A
- AVTX N/A
- P/E Ratio
- ULBI $11.21
- AVTX N/A
- Revenue Growth
- ULBI 3.66
- AVTX N/A
- 52 Week Low
- ULBI $4.14
- AVTX $4.44
- 52 Week High
- ULBI $13.39
- AVTX $17.49
- Technical
- Relative Strength Index (RSI)
- ULBI 32.50
- AVTX 29.58
- Support Level
- ULBI $4.14
- AVTX $4.59
- Resistance Level
- ULBI $4.87
- AVTX $5.85
- Average True Range (ATR)
- ULBI 0.39
- AVTX 0.85
- MACD
- ULBI -0.00
- AVTX -0.21
- Stochastic Oscillator
- ULBI 10.29
- AVTX 2.41
About ULBI Ultralife Corporation
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).